Bimatoprost

證據等級: L5

預測適應症: 10 個

Bimatoprost: From Glaucoma / Eyelash Hypotrichosis to Alopecia

One-Sentence Summary

Bimatoprost is a synthetic prostamide F2α analogue originally approved for reducing intraocular pressure in open-angle glaucoma and ocular hypertension, and subsequently FDA-approved as Latisse for eyelash hypotrichosis. The TxGNN model predicts it may be effective for Alopecia (scalp hair loss), with 11 clinical trials and 20 publications currently supporting this direction. Evidence from multiple completed Phase 2 RCTs in androgenetic alopecia — collectively enrolling over 850 subjects — provides a substantive clinical basis for this prediction.

Quick Overview

Item	Content
Original Indication	Open-angle glaucoma / ocular hypertension; eyelash hypotrichosis (Latisse)
Predicted New Indication	Alopecia
TxGNN Prediction Score	99.99%
Evidence Level	L2
Saudi Arabia Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Bimatoprost is a synthetic prostamide / prostaglandin F2α (FP) receptor agonist. Its primary pharmacological action involves activating FP receptors on the ciliary body to reduce intraocular pressure in glaucoma. A striking side effect observed in patients using prostaglandin analogue eyedrops — hypertrichosis, darkening, and lengthening of eyelashes — redirected research attention toward hair loss. This led directly to FDA approval of bimatoprost 0.03% solution (Latisse) for eyelash hypotrichosis, providing regulatory-grade confirmation that FP receptor activation promotes hair follicle growth in humans.

The mechanistic link to scalp alopecia is biologically coherent: FP receptor activation prolongs the anagen (active growth) phase of the hair follicle cycle and suppresses catagen (regression) induction. This same mechanism that lengthens and thickens eyelashes applies to scalp hair follicles, irrespective of the alopecia subtype — whether androgenetic (DHT-driven follicle miniaturisation), areata (autoimmune T-cell attack on hair follicle immune privilege), or chemotherapy-induced. The prostaglandin pathway's role in regulating hair follicle cycling is well-supported in the mechanistic literature.

Multiple Phase 2 clinical trials have now tested topical bimatoprost for androgenetic alopecia (AGA) in men and women (three trials, combined n > 850), with additional completed studies in alopecia areata. The Latisse approval provides an anchored L1 proof of concept that validates the FP receptor hypothesis in humans, making the extrapolation to scalp alopecia pharmacologically credible.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01325337	Phase 2	Completed	307	Large double-blind RCT comparing 3 doses of bimatoprost solution vs vehicle and OTC minoxidil 5% in men with androgenic alopecia; one of three pivotal Phase 2 trials
NCT01325350	Phase 2	Completed	306	Large double-blind RCT of 3 doses of bimatoprost solution vs vehicle and OTC minoxidil 2% in women with female pattern hair loss (FPHL)
NCT01904721	Phase 2	Completed	244	Safety and efficacy of bimatoprost in male androgenic alopecia; third major Phase 2 trial bringing combined Phase 2 enrolment to >850 subjects
NCT02170662	Phase 2	Completed	33	Mechanistic validation study — effect of bimatoprost 0.03% ophthalmic solution on androgen-dependent scalp hair follicle growth
NCT05600673	Phase 1/2	Completed	30	CO2 fractional laser combined with bimatoprost 0.03% for alopecia areata — evaluates synergistic immune modulation and follicle stimulation
NCT01189279	Phase 1	Completed	42	Safety, tolerability, and pharmacokinetics of new bimatoprost formulations following topical scalp application in alopecia patients
NCT02848300	Phase 1	Completed	11	Local pharmacokinetics and tolerability after 14 days of once-daily topical application of two bimatoprost formulations to the scalp in male AGA
NCT01023841	Phase 4	Completed	71	Safety and efficacy of bimatoprost 0.03% vs vehicle on upper eyelid margins in paediatric eyelash hypotrichosis — corroborates the safety profile across age groups
NCT02676310	Phase 1	Terminated	53	Dose escalation safety and PK study for male AGA — terminated early before reaching target enrolment; termination reason requires clarification to rule out safety signals
NCT00187577	N/A	Completed	14	Randomised investigator-masked study comparing latanoprost vs bimatoprost ophthalmic solutions for eyelash regrowth in alopecia areata

Literature Evidence

PMID	Year	Type	Journal	Key Findings
40252129	2025	RCT / Clinical Study	Archives of Dermatological Research	CO2 fractional laser combined with bimatoprost 0.03% in alopecia areata — evaluates synergistic hair regrowth via immune modulation and FP receptor activation
37089845	2023	Prospective Non-Randomised Trial	Indian Dermatology Online Journal	Bimatoprost vs clobetasol propionate in scalp alopecia areata — positions bimatoprost as a viable newer treatment modality in clinical comparison
35278027	2022	Prospective Cohort	Dermatologic Therapy	Topical bimatoprost for eyelash loss in alopecia totalis and universalis — 16 of 19 subjects achieved eyelash regrowth at mean 30.6 weeks
32250713	2022	Systematic Review	Journal of Dermatological Treatment	Network meta-analysis of non-surgical AGA monotherapies in men and women — places bimatoprost within the comparative evidence landscape
28264599	2017	Review	Expert Opinion on Investigational Drugs	Comprehensive bimatoprost-specific review covering mechanism, clinical trial evidence, and applications across eyelash, eyebrow, and scalp alopecia subtypes
29854658	2018	Review	Indian Dermatology Online Journal	Bimatoprost in dermatology — traces the pathway from glaucoma side effect to alopecia and vitiligo applications
29863806	2018	Clinical Guideline	The Journal of Dermatology	Japanese 2017 evidence-based guideline for male-pattern and female-pattern hair loss — updated framework for evaluating AGA treatments
30865404	2019	Clinical Case / Review	Dermatology Online Journal	Laser-assisted delivery of bimatoprost, PRP, and minoxidil for androgenetic alopecia — explores enhanced topical penetration via ablative fractional photothermolysis channels
35040730	2022	Formulation Study	Drug Delivery	Optimised topical bimatoprost formulation achieving 4.6-fold higher human skin flux and 529% increase in dermal deposition — supports scalp delivery feasibility
38577618	2024	Drug Delivery Research	International Journal of Pharmaceutics: X	Spanlastic vesicular nanocarrier for bimatoprost scalp delivery — superior cutaneous deposition and hair regrowth efficacy demonstrated in androgenic alopecia model

Saudi Arabia Market Information

Bimatoprost is currently not registered or marketed in Saudi Arabia. No product licences have been issued by the Saudi Food and Drug Authority (SFDA) for bimatoprost in any dosage form or indication. This represents a regulatory gap: while the drug carries FDA approval in two indications (Lumigan for glaucoma; Latisse for eyelash hypotrichosis) and is marketed in multiple international markets, a de novo SFDA registration would be required before any commercial or clinical programme could proceed in Saudi Arabia.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Three large Phase 2 RCTs (combined n > 850) have evaluated topical bimatoprost for androgenetic alopecia in both men and women, with additional completed studies in alopecia areata. The FDA-approved eyelash indication (Latisse) provides regulatory-grade proof of concept for the prostaglandin FP receptor mechanism in human hair follicles, anchoring the scalp alopecia hypothesis in validated pharmacology.

To proceed, the following is needed:

Phase 3 RCT data for scalp alopecia — this is the critical evidence gap; no Phase 3 trial has been completed for any scalp alopecia subtype
SFDA registration pathway assessment — bimatoprost is not marketed in Saudi Arabia and a new marketing authorisation application would be required
Clarification of NCT02676310 early termination — the Phase 1 dose escalation study was stopped before full enrolment; the reason must be reviewed to rule out scalp-specific safety signals at higher doses
Formal MOA documentation — DrugBank mechanism of action data should be retrieved to support pharmacological dossier preparation
Validated scalp delivery formulation — ophthalmic formulations are not directly transferable to the scalp; multiple formulation optimisation studies exist but require regulatory-grade validation before clinical use
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.